Stock SLRN ACELYRIN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Acelyrin, Inc.

Equities

SLRN

US00445A1007

Real-time Estimate Cboe BZX
Other stock markets
 02:04:16 2024-05-10 pm EDT 		5-day change 1st Jan Change
4.625 USD -5.23% Intraday chart for Acelyrin, Inc. +7.47% -37.33%
May. 09 Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024 CI
May. 09 Acelyrin, Inc. Announces CEO Changes CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wells Fargo Raises ACELYRIN's Price Target to $13 From $11, Keeps Equalweight Rating
MT
Wells Fargo Starts Coverage on ACELYRIN with Equalweight Rating, $11 Price Target
MT
Citigroup Initiates ACELYRIN at Neutral Rating With $8 Price Target
MT
Morgan Stanley Adjusts Price Target on ACELYRIN to $13 From $19, Maintains Equal-Weight Rating
MT
Jefferies Adjusts ACELYRIN Price Target to $12 From $15, Maintains Buy Rating
MT
Morgan Stanley Downgrades ACELYRIN to Equalweight From Overweight, Cuts Price Target to $19 From $39
MT
Morgan Stanley Adjusts Price Target on Acelyrin to $39 From $29, Maintains Overweight Rating
MT
HC Wainwright Starts Acelyrin at Buy, $44 Price Target
MT
Morgan Stanley Initiates Coverage on Acelyrin With Overweight Rating, $29 Price Target
MT
Jefferies Starts Acelyrin at Buy With $31 Price Target
MT
Piper Sandler Initiates Acelyrin at Overweight With $68 Price Target
MT
TD Cowen Starts Acelyrin at Outperform
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLRN Stock
  4. News Acelyrin, Inc.
  5. Analyst Reco.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW